Form 13-F position report

FENNEC PHARMACEUTICALS INC

Reported by STATE STREET CORPORATION

FENC CUSIP 31447P100 Manager CIK 0000093751

Reported 425,689 shares, down 315 (0.1%) from the prior quarter.

Reported value -1.0%; share count -0.1% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 425,689 Quarter-end amount reported
Reported value $4,533,588 Fair value at quarter end
Consecutive quarters held 14 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-06-30 2308913
2023-09-30 1963369
2023-12-31 2980593
2024-03-31 3375131
2024-06-30 1962569
2024-09-30 1641295
2024-12-31 2146986
2025-03-31 2059230
2025-06-30 2792900
2025-09-30 3193641
2025-12-31 2716368
2026-03-31 2208188
2026-06-30 4579543
2026-09-30 4533588

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for FENNEC PHARMACEUTICALS INC held by STATE STREET CORPORATION.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 425,689 -315 (-0.1%) < 0.01% $4,533,588 2026-11-12
Q2 2026 Added 426,004 +66,949 (18.6%) < 0.01% $4,579,543 2026-08-07
Q1 2026 Added 359,055 +6,280 (1.8%) < 0.01% $2,208,188 2026-05-15
Q4 2025 Added 352,775 +11,574 (3.4%) < 0.01% $2,716,368 2026-02-13
Q3 2025 Added 341,201 +4,707 (1.4%) < 0.01% $3,193,641 2025-11-14
Q2 2025 Reduced 336,494 -1,639 (-0.5%) < 0.01% $2,792,900 2025-08-14
Q1 2025 Reduced 338,133 -1,580 (-0.5%) < 0.01% $2,059,230 2025-05-15
Q4 2024 Added 339,713 +11,454 (3.5%) < 0.01% $2,146,986 2025-02-14
Q3 2024 Added 328,259 +7,053 (2.2%) < 0.01% $1,641,295 2024-11-14
Q2 2024 Added 321,206 +17,687 (5.8%) < 0.01% $1,962,569 2024-08-14
Q1 2024 Added 303,519 +37,869 (14.3%) < 0.01% $3,375,131 2024-05-15
Q4 2023 Added 265,650 +4,216 (1.6%) < 0.01% $2,980,593 2024-02-14
Q3 2023 Reduced 261,434 -51 (0.0%) < 0.01% $1,963,369 2023-11-14
Q2 2023 New 261,485 +261,485 (0.0%) < 0.01% $2,308,913 2023-08-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

125 managers reported FENNEC PHARMACEUTICALS INC for Q3 2026.

Managers reporting FENNEC PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Rosalind Advisors Inc Unchanged 3,188,001 0 10.89% $33,952,211 8 qtrs
AIGH Capital Management LLC Added 2,499,421 +13,383 2.68% $26,618,834 7 qtrs
BlackRock Inc Added 2,033,398 +306,329 < 0.01% $21,655,690 9 qtrs
Solas Capital Management LLC Reduced 1,433,282 -456,084 8.52% $15,264,453 30 qtrs
AWM Investment Company Inc Unchanged 1,160,296 0 1.19% $12,357,152 4 qtrs
Prospect Capital Advisors LLC Added 886,600 +388,800 4.66% $9,442,290 2 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Unchanged 839,306 0 < 0.01% $8,938,609 3 qtrs
STATE STREET CORPORATION This report Reduced 425,689 -315 < 0.01% $4,533,588 14 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 409,061 +6,495 < 0.01% $4,356,498 26 qtrs
ESSEX INVESTMENT MANAGEMENT CO LLC New 318,771 +318,771 0.5% $3,394,911 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 12, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
58,031
Shared
0
None
367,658

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.